Testing a safe dose of dapagliflozin for type 1 diabetes
Treatments studied
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This study tests a medication called dapagliflozin, which is usually for type 2 diabetes, to see if it can be used safely in people with type 1 diabetes. It focuses on preventing a serious side effect called ketoacidosis, where the blood becomes too acidic.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 24 and 85 years old.
- You have had type 1 diabetes for at least 1 year.
- You use insulin (either multiple daily injections or an insulin pump) and your total daily dose is at least 0.4 units per kilogram of body weight.
- Your most recent HbA1c (a measure of blood sugar control) is less than 10%.
- You eat at least 100 grams of carbohydrates per day.
- You are willing to follow the study plan and can do high-intensity exercise (for a sub-study).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether using a dual continuous glucose and ketone monitor can help people with type 1 diabetes safely take a class of drugs called SGLT2 inhibitors, which may improve blood sugar control but can increase the risk of diabetic ketoacidosis (DKA). By closely monitoring changes in glucose and ketone levels, the study aims to prevent dangerous episodes while benefiting from the drug's effects.
This trial tests a medication called dapagliflozin (often used in type 2 diabetes) to see if it can help protect the kidneys in people with type 1 diabetes who already have some signs of kidney damage. If it works, it could slow down further kidney decline.
This trial tests if a drug called dapagliflozin (an SGLT2 inhibitor) can help prevent complications in people with prediabetes when added to lifestyle changes. It aims to see if this approach works better than lifestyle changes alone.
This trial tests how two diabetes medications, SGLT2i and pioglitazone, affect ketone production in people with type 1 diabetes. It aims to find new ways to improve blood sugar control.
This study tests whether a medication called an SGLT2 inhibitor is safe for people with type 1 diabetes. It aims to lower blood sugar without increasing the risk of dangerous complications.
This study is testing two different diabetes pills—dapagliflozin or pioglitazone—in people with type 2 diabetes. The goal is to see which one works better when added to your current metformin and DPP-4 inhibitor. You may qualify if your blood sugar is not well controlled with your current medications.
Hear when a new Type 1 Diabetes Mellitus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.